Abstract:Systemic mastocytosis (SM) is a subset of rare neoplasms characterized by clonal proliferation of aberrant mast cells (MCs) and their accumulation in >= 1 extracutaneous organs, which typically associates with activating KIT mutations.(1) SM with an associated hematological neoplasm (AHN) is the second most common type of SM in Mayo series (similar to 40%),(2) with challenging diagnosis because the mast cell infiltration may hide behind the AHN component and vice versa.(3-5) This is particularly applicable to acute myeloid leukemia (AML) because the histological examination of bone marrow (BM) has not been established as a standard diagnostic tool. Moreover, the concomitant hematological neoplasm often shares a KIT mutation and/or other clonal genetic abnormalities with neoplastic MCs. AML with t(8;21) (q22;q22)/RUNX1::RUNX1T1 [t(8;21) AML] represents 4% to 8% of all AMLs, which is categorized to the genetically favorable risk group.(6) Meanwhile, KIT mutations, most frequently at position D816, are detectable in up to 20% to 47% of patients with t(8;21) AML and associate with decreased remission duration and inferior overall survival (OS).(7-10) Previous case reports, case-series, and/or literature reviews have described the potential association of KIT mutant t(8;21) AML [KITpos t(8;21) AML] with underlying SM.(11)(,)(12) Owing to a lack of literature on investigating similarities and differences between SM-t(8;21) AML and KITpos t(8;21) AML, we carried out this retrospective cohort study from multiple Chinese centers to compare clinical and molecular features between these 2 groups. Between January 2009 and December 2022, 24 patients with SM-t(8;21) AML and 212 with KITpos t(8;21) AML diagnosed and treated in 16 Chinese centers were eligible. All patients were screened for SM by BM smear, flow cytometry, and/or BM histological examination. Details of the study design, patient population, treatment regimen, and statistical analysis have been described in supplemental Data. This study was approved by the responsible ethics committees and performed in accordance with the Declaration of Helsinki.

Mast cell sarcoma with KIT p.D816V mutation and concurrent systemic mastocytosis

Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature

Systemic Mastocytosis Mimicking Blastic Plasmacytoid Dendritic Cell Neoplasm: a Case Report

Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow

Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity

Primary Mast Cell Sarcoma of the Maxillary Sinus and Gingiva Mimicking Malignant Neuroendocrine Tumor: A Case Report

Prevalence and impact of the KIT M541L variant in patients with mastocytosis

Diagnosis of systemic mastocytosis with cryptic deletion of TET2 and DNMT3A resulting from unbalanced translocation

A Multicenter Retrospective Comparison Between Systemic Mastocytosis with T(8;21) AML and KIT Mutant T(8;21) AML.

Systemic mastocytosis with an associated hematological neoplasm (acute myeloid leukaemia with RUNX1::RUNX1T1 fusion) – A case study

KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes

Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation

Ovarian germ cell tumor/mastocytosis with KIT mutation: A unique clinicopathological entity

Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis

Eosinophilia in a Patient with Aggressive Systemic Mastocytosis Harboring a KIT D816V Mutation: A Case Report.

A multi-center retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML

A Rare Case of Aggressive Systemic Mastocytosis Involving the Gastrointestinal System and Review of Literature

A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosis

Acute Myeloid Leukemia with T(8;21)(q22;q22.1)/runx1-Runx1t1 and KIT Exon 8 Mutation is Associated with Characteristic Mastocytosis and Dismal Outcomes

How, When, and Why

How I diagnose systemic mastocytosis